IMPORTANT NOTE: You may submit your article only through our online submission systemSubmit your manuscript

The aim of the International Institute of Anticancer Research (IIAR) is to provide an independent platform for international cooperation in the fight against cancer.
The IIAR will advance, protect and support throughout the world the ideals of freedom, peace, health, scientific knowledge, equality, welfare and mutual respect among communities in science and life.This site provides information on the aims and activities of the IIAR, including current cancer research projects and invitations for cooperation.
The IIAR is supported by the four international peer-reviewed journals ANTICANCER RESEARCH, IN VIVO, CANCER GENOMICS & PROTEOMICS and CANCER DIAGNOSIS & PROGNOSIS.

Editorial office: 111 Bay Avenue, Highlands, NJ 07732, USA.
Mailing address: Anticancer Research USA, Inc., P.O.B. 280, Belmar, NJ 07719, USA.

Anticancer Research

Anticancer Research is an international print and online monthly journal designed to rapidly publish peer-reviewed original works and reviews on all aspects of experimental and clinical cancer research.
Established: 1981

Impact factor (2021): 2.435

Current issue contents >>

In Vivo

In Vivo is an international online and open-access journal designed to bring together peer-reviewed original works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management.
Established: 1987

Impact factor (2021): 2.406

Current issue contents >>

Cancer Genomics & Proteomics

Cancer Genomics & Proteomics is an international peer-reviewed online and open-access journal designed to rapidly publish high quality articles and reviews on the application of genomic and proteomic technology to experimental and clinical cancer research.
Established: 2004

Impact factor (2021): 3.395

Current issue contents >>

Cancer Diagnosis & Prognosis

Cancer Diagnosis & Prognosis is an international online open-access peer-reviewed journal, designed to rapidly publish original and review papers on experimental and clinical research advancing the knowledge on the diagnosis and prognosis of all types of cancer, leukemia and metastasis.
Established: 2021

Current issue contents >>

Special Issue on Emerging Technologies in Cancer Research

High-throughput genomic technologies continuously advance and offer new opportunities to better understand and treat cancer. The past decade has seen a plethora of next-generation sequencing and data analysis studies, allowing us to map the genomic landscapes of various cancer types, while single cell analyses are shedding light on tumor heterogeneity. Groundbreaking new technologies, such as spatial omics, can give us unprecedented insight into the spatiotemporal tumor architecture and micro-environment. In this regard, this special issue aims to bring together review articles, experimental and clinical studies on the following topics:

– Whole-genome sequencing
– Single-cell genomics
– Mutational signatures
– Spatial transcriptomics
– Epigenomics
– Multi-omics
– Tumor architecture
– Tumor progression
– Data analysis methods / bioinformatics /machine learning
– Tumor heterogeneity
– Circulating tumor cells
– Precision medicine
– Tumor microenvironment interactions
– Computational immunology
– New therapeutic targets

Publication date: December 1, 2023; Submission deadline: November 3, 2023.
Instructions for the preparation and submission of reviews and original articles.

Anticancer Research, In Vivo, Cancer Genomics & Proteomics, and Cancer Diagnosis & Prognosis are independent international journals, published by the International Institute of Anticancer Research (IIAR), and have had no relation or association with other publishers since their establishment.

At the IIAR, we are committed to maintaining the highest content quality and the most rapid processing of submitted articles to our four journals.

All submitted articles are peer-reviewed to secure a valid assessment. Our preliminary review includes a detailed assessment of the suitability and validity of the conclusions of all cited references.

We value the support of our policy by our Authors and Readers and we look forward to receiving comments and suggestions for the
continuous improvement of our services.

Now you can access the entire contents of the IIAR journals published from 2013 till today
with ease on your Android©  or iOS phone or tablet with our newly designed app, freely available on Google Play Store and App Store


Articles in ANTICANCER RESEARCH are fully available to everyone as open access 2 years after publication.
IN VIVO (from January 2017) and CANCER GENOMICS & PROTEOMICS (from January 2013) are published online-only with open access.
CANCER DIAGNOSIS & PROGNOSIS (from March 2021) is published online-only with open access.


Should you come across any errors in this website, please inform:

IMPORTANT NOTE: You may submit your article only through our online submission system